Stockwinners Market Radar for January 07, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:53 EST Golden Bull notified by Nasdaq that it is not in compliance with listing rules - Golden Bull Limited announced that it has been notified by Nasdaq that since the company had not yet filed its Form 6-K financial statements for the six-month period ended June 30, 2019, it no longer complies with the Listing Rules for continued listing. The company was given 60 days to submit a plan to regain compliance. The company previously announced that it had shutdown its peer-to-peer lending business in China and has taken the right steps since March 2018 to position the company in the car rental business and bitcoin mining business. The company intends to file its Form 6-K on or before January 31, 2020 with six-month financial statements and to regain compliance with Nasdaq Listing Rules.

18:37 EST Maxim Integrated files patent infringement suit against Monolithic Power Systems - Volterra Semiconductor, a wholly owned subsidiary of Maxim Integrated Products (MXIM), announced that it has filed a complaint in the U.S. District Court for the District of Delaware against Monolithic Power Systems (MPWR). The complaint asserts that MPS DC-to-DC power converter products infringe multiple Volterra patents related to coupled inductor technology, including U.S. patent numbers 6,362,986, 7,525,408 and 7,772,955. Volterra is seeking damages from MPS and an order prohibiting MPS from selling the infringing products.

18:25 EST Fly Intel: After Hours Movers - HIGHER: ShiftPixy (PIXY), up 200.7% after completing its recapitalization... Galera (GRTX), up 12.8% after announcing initial dosing in its Phase 2a clinical trial of GC4419... Greenlane (GNLN), up 12.6% after announcing a distribution agreement with AVD... Cumberland (CPIX), up 1.9% after announcing the national launch of a new Caldolor ready-to-use product. DOWN AFTER EARNINGS: EXFO (EXFO), down 16.1%. ALSO LOWER: Livent (LTHM), down 13.3% after providing guidance for Q4, fiscal 2019, and fiscal 2020... RADA Electronic (RADA), down 8.4% after it filed to sell common stock... SeaSpine (SPNE), down 4.3% after providing Q4 and FY20 revenue guidance... PNM Resources (PNM), down 3.2% after it filed to sell 4.9M shares of common stock.

18:14 EST ShiftPixy completes recapitalization - ShiftPixy announced the assignment of 60% of its contracted book of business for $20M. The company expects proceeds to fully fund operations through to cash flow breakeven, including the ongoing successful development of its next-gen workforce platform, and to further fulfill its growth initiatives. Given the company's early calendar year 2020 business outlook, its accelerating growth profile, and an enhanced focus on its most profitable customers resulting from the assignment, ShiftPixy expects to quickly replace the revenue stream and achieve cash flow breakeven by mid calendar year 2020.

17:41 EST AmeriLife enters recapitalization agreement with group led by THL, Cannae - AmeriLife Group announced that it has entered into a recapitalization agreement with an investor group led by Thomas H. Lee Partners, L.P., a premier private equity firm investing in growth companies, and other investors including Cannae Holdings and certain THL limited partners. Terms of the transaction, which is expected to close in the first quarter of 2020 subject to customary closing conditions, were not disclosed. THL is acquiring a majority stake from J.C. Flowers & Co., LLC, a private investment firm dedicated to investing globally in the financial services industry, and other investors. "We are excited to partner with THL in the next phase of our growth, building upon the success of our more than four-year relationship with J.C. Flowers & Co.," said Scott R. Perry, CEO of AmeriLife. "THL has a strong track record of partnering with management to add long-term, sustainable value to great companies like AmeriLife. THL's deep industry expertise and financial and operational resources will enhance AmeriLife's capabilities and provide financial flexibility to accelerate our growth."

17:31 EST United Airlines sees Q4 non-cash impairment charge of $90M related to HK routes - For fourth quarter 2019, United Airlines expects to record a special non-cash impairment charge of $90M associated with its Hong Kong routes. The company conducted its annual impairment review of intangible assets in the fourth quarter of 2019, which consisted of a comparison of the book value of specific assets to the fair value of those assets calculated using the discounted cash flow method. Due to a decrease in demand for the Hong Kong market and the resulting decrease in unit revenue, the company determined that the value of its Hong Kong routes had been fully impaired. Notwithstanding such impairments, the collateral pledged under the company's term loan continues to be sufficient to satisfy the loan covenants.

17:25 EST Gol Linhas reports preliminary December traffic figures - GOL Linhas Aereas Inteligentes announces preliminary air traffic figures for the month of December 2019. GOL's total supply, or ASK, was 3.1% higher, with an 8.2% increase in seats and a 7.3% increase in departures. GOL's total demand, or RPK, increased by 1.1% in comparison to December 2018 and consolidated load factor was 82.0%. GOL's domestic supply, or ASK, increased 5.2% and demand, or RPK, increased by 3.1%. GOL's domestic load factor was 83.0%, a 1.7 p.p. decrease in comparison to December 2018. The volume of departures increased by 7.5% and seats increased by 8.5% over December 2018. GOL's international supply, or ASK, and demand, or RPK, decreased by 9.3% and 12.0% respectively, and international load factor was 74.6%, a decrease of 2.3 p.p. in relation to December 2018.

17:01 EST Greenlane, AVD announce distribution agreement - Advanced Vapor Devices, or AVD, and Greenlane Holdings (GNLN) announced a comprehensive distribution agreement for AVD products, including its entire suite of glass and resin cartridges, glass disposable cartridges, and rechargeable and disposable batteries. Under the terms of the agreement, Greenlane will distribute AVD's Easy-Press Glass Cartridge, the industry's first glass cartridge with a thumb snap-on, tamper-proof locking system, which is designed to reduce bottlenecks in rapid high-end, high-production filling and capping environments.

16:54 EST Livent down 21.5% after lowering Q4, FY19 guidance

16:39 EST Red Robin says COO Guy Constant leaving company - On January 7, the company announced Guy J. Constant's employment with Red Robin Gourmet Burgers was terminated without cause. Mr. Constant served as Executive Vice President and Chief Operating Officer of the Company from January 2019 until his departure, and prior to that served as Executive Vice President and Chief Financial Officer since December 2016. The Company will immediately commence an external search for a new Chief Operating Officer. Effective immediately and during the external search, Senior Vice President and Chief People Officer, Michael Buchmeier, will assume responsibility for the Company's operations as interim Chief Operating Officer

16:32 EST Sprouts Farmers Market announces Denise Paulonis to join as CFO - Sprouts Farmers Market (SFM) announced that Denise Paulonis will join the company asCFO, effective February 21. Paulonis most recently served as executive vice president and chief financial officer of The Michaels Companies (MIK), the largest arts and crafts specialty retailer in North America, and brings more than twenty-five years of experience in finance, accounting, investor relations, corporate strategy, tax, treasury, supply chain, and risk management. "We are absolutely delighted to welcome Denise to Sprouts as our new CFO," said Jack Sinclair, chief executive officer and a director of Sprouts Farmers Market. "Denise's deep experience in specialty retail and financial acumen will be invaluable to our leadership team as we chart the long-term strategy of our company." Paulonis joined Michaels in 2014 and prior to her service as executive vice president and chief financial officer from 2016 to 2019, served in various finance roles within the organization, including senior vice president of finance and treasurer, and vice president of corporate finance, investor relations and treasury.

16:30 EST Saia names Douglas Col CFO - Saia announced that Douglas Col has been promoted to Vice President and Chief Financial Officer, effective immediately. Col replaces Robert Chambers who returned to his prior employer in a senior executive position after eight months with Saia. Col joined Saia in 2014 as Vice President and Treasurer assuming leadership for the company's bank relationships, risk management programs and investor relations. Prior to joining Saia, Col spent over twenty years working with transportation-related businesses as an investment analyst, equity fund manager and investment banker.

16:16 EST Farmers National Banc announces completion of merger with Maple Leaf Financial - Farmers National Banc Corp., the holding company for The Farmers National Bank of Canfield, announced that it completed the merger of Maple Leaf Financial, the holding company for Geauga Savings Bank into FMNB Merger Subsidiary III, a newly-formed, wholly-owned subsidiary of Farmers, and the merger of Geauga Savings Bank into Farmers National Bank.

16:16 EST Pzena Investment reports preliminary AUM $41.2B at December 31, 2019 - Compared to $33.4B as of December 31, 2018.

16:10 EST Peapack-Gladstone appoint Maureen Hemhauser Chief Risk Officer - Peapack-Gladstone Financial Corporation and Peapack-Gladstone Bank announce the elevation of Maureen Hemhauser to executive VP, Chief Risk Officer and Head of Compliance at Peapack-Gladstone Bank. In her current role, Hemhauser is responsible for administering the Bank's Enterprise Risk Management Program and overseeing the Bank's Regulatory Compliance, Bank Secrecy Act, OFAC and Anti-Money Laundering programs. Hemhauser was senior VP, Chief Compliance Officer at Peapack-Gladstone Bank since February 2015.

16:08 EST SeaSpine up 2.3% after giving Q4, FY20 revenue guidance

16:08 EST Ascena Retail regains share price compliance with Nasdaq minimum bid price rule - Ascena retail group announced that the Company received written notice from The Nasdaq Stock Market stating that the Company successfully regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market set forth in Nasdaq Listing bid price rule.

16:06 EST Synopsys to acquire certain IP assets of INVECAS, terms not disclosed - Synopsys announced that it has signed a definitive agreement to acquire certain IP assets of INVECAS, headquartered in Santa Clara, California. This acquisition will broaden Synopsys' DesignWare Logic Library, General Purpose I/O, Embedded Memory, Interface and Analog IP portfolio. The acquisition will also add a team of experienced R&D engineers to accelerate Synopsys' physical IP roadmap across a range of process technologies to address customers' evolving design requirements in markets such as consumer, IoT and automotive. INVECAS will retain its HDMI IP and ASIC Design Solutions businesses. The transaction, which is expected to close the first half of fiscal 2020 and is subject to customary closing conditions, is not material to Synopsys' financials. Terms are not being disclosed.

16:03 EST Northwoods Energy announces strong production results in Powder River Basin - Northwoods Energy, supported by investment funds affiliated with Apollo Global Management, announced initial results from three recently completed wells, targeting three separate formations, Shannon, Niobrara, and Frontier, in Converse County, Wyoming. Shannon Formation - The Aspen 11W02-3SH generated an IP 24 hour rate of 1,860 barrels of oil equivalent per day ("boe/d") (92% oil), an IP 30 day rate of 1,500 boe/d, 91% oil, from a 9,864-foot lateral length,152 boe/d per 1,000' lateral, and produced approximately 120,000 boe, 89% oil,in the first 90-days.

15:46 EST Bitcoin Investment Trust spikes higher after tensions escalate in Middle East - Shares of the Bitcoin Investment Trust are up 88c per share or 9.6% to $9.85 per share amid U.S.-Iran tensions.

15:35 EST Intel says SAIC to use Mobileye's REM mapping technology - "Mobileye's global ambitions in advanced driver-assistance systems and autonomous mobility-as-a-service came into sharper focus with two agreements announced today," reported parent company Intel. Chinese OEM SAIC plans to use Mobileye's REM mapping technology to map China for L2+ ADAS deployment while paving the way for autonomous vehicles in the country. Additionally, the leaders of Daegu Metropolitan City, South Korea, agreed to establish a long-term cooperation to deploy MaaS based on Mobileye's self-driving system, Intel announced.

14:52 EST Zovio announces LOI to convert and separate Ashford - Zovio announced last night that on December 30, 2019, it had entered into a non-binding Letter of Intent, or "LOI," with the Ashford University nonprofit entity. As previously disclosed, the Company has been planning a change of ownership and conversion of Ashford which would ultimately result in Ashford being owned and operated by AU NFP, a nonprofit California public benefit corporation that was formed for the purpose of the conversion transaction and is independent of the company. The LOI contemplates that the company, Ashford and AU NFP would enter into an agreement and plan of conversion pursuant to which the company, in exchange for $1.00 and entry into a services agreement would cause Ashford to separate from the company through a series of conversion and merger transactions ultimately resulting in Ashford, inclusive of all of the operations and assets constituting Ashford, being independently owned and operated by AU NFP. The parties also contemplate entering into a transition services agreement, pursuant to which the company would provide identified services to AU NFP for a period of time. "We believe the conversion and separation of Ashford University is clearly in the best interests of Ashford's students, faculty, staff and alumni to return to the historical nonprofit status the institution held in 2005, while at the same time, allowing Zovio to pursue diversified growth providing technology and services to other institutions, corporations and learners," commented Andrew Clark, Founder, President and CEO of Zovio.

14:42 EST Arizona AG files consumer fraud lawsuit against Juul Labs - Attorney General Mark Brnovich announced that his office filed a Consumer Fraud lawsuit against Juul Labs regarding the advertisement and sale of JUUL's vaping devices and vaping pods to Arizonans, including JUUL's exploitative marketing towards Arizona's youth. The lawsuit was filed Tuesday morning in Maricopa County Superior Court. Juul Labs is 35% owned by Altria (MO). Reference Link

14:23 EST Ford CEO James Hackett sells 20K shares of company stock - Ford CEO James Hackett disclosed in a regulatory filing that he had sold 20,000 shares of company stock on January 3 at an average price of $9.29. The total transaction value of the sale was $185,800.

13:46 EST M/I Homes rallies after Q4 homes delivered rises 5% to 1,921 - M/I Homes earlier today disclosed preliminary results for homes delivered, new contracts and sales backlog for its Q4 and year ended December 31, 2019. Homes delivered in Q4 increased 5% from the comparable period in the prior year to 1,921 deliveries, and homes delivered for the twelve months ended December 31, 2019 increased 9% from 2018 to 6,296 deliveries. New contracts for Q4 increased 43% from last year to 1,677 contracts, and contracts for the twelve months ended December 31, 2019 increased 16% from 2018 to 6,773 contracts. Homes in backlog increased 22% to 2,671 units with a sales value of $1.058B, and the average sales price in backlog decreased 3% to $396,000, in each case, at December 31, 2019 compared to the end of 2018. At December 31, 2018, there were 2,194 homes in backlog with a sales value of $897M, and the average sales price in backlog was $409,000. Shares of M/I Homes are up 3% to $41.73 in afternoon trading.

13:41 EST Micron sees 'very strong' tailwind from rising memory content in autos

13:22 EST Beyond Meat competitor Impossible Foods introduces pork product made from plants - Beyond Meat competitor Impossible Foods introduced products called Impossible Pork Made from Plants and Impossible Sausage Made from Plants at CES 2020 on Monday. The Fly notes that Impossible Foods has not had an IPO. Reference Link

13:03 EST Delta Air Lines enters partnership with Sarcos Robotics - Delta Air Lines is partnering with Sarcos Robotics to explore "new employee technology fit for a superhero" - a mobile and dexterous exoskeleton designed to boost employees' physical capabilities and bolster their safety. Delta plans to test the technology in a pilot location during the first quarter of 2020, giving employees the opportunity to experience the tech in a real-world setting and provide additional feedback on its functionality. In addition to enabling superhuman strength for extended periods, the robotic suit may also level the playing field in terms of physical capacity. Roles that have historically been limited to those who meet specific strength requirements could potentially be performed by a more diverse talent pool, thanks to wearable robotics.

12:35 EST BLS Pharma alleges Inovio breached contract for injection system - BLS Pharma filed a complaint late last month against Genetronics and Inovio Pharmaceuticals (INO) for breaching a contract to supply a needle-free injection system that BLS Pharma was using to develop a drug-device combination, or DDC, for testosterone replacement therapy. The shareholders of BLS Pharma previously developed the needleless injector technology, called "Zetajet," and sold the intellectual property rights for it to Inovio and Genetronics, with the condition that Genetronics would execute a license and supply agreement to supply Zetajet units to BLS Pharma upon request. Under the agreement, BLS Pharma ordered 25,000 Zetajet units to prepare for its clinical trials on the DDC and was assured that the order was "in process." In September, BLS Pharma and Genetronics discussed the logistics of the syringe supply, and BLS Pharma's plan to offer the product for patients with hypogonadism and as a treatment for transgender males. The next business day, Inovio and Genetronics informed BLS Pharma they would not be supplying the syringes. This breach of contract eliminated BLS Pharma's ability to bring the DDC to market. "We are disappointed that we cannot offer this solution for male hypogonadism and to the transgender community, who have historically been marginalized by the medical and pharmaceutical community," stated Mark Logomasini, CEO of BLS Pharma. The testosterone treatment market is valued at $1.3B-$1.8B dollars annually. BLS Pharma estimated its lost profits due to the breach of contract to be at least $72.9M.

12:31 EST Acme United subsidiary acquires assets of First Aid Central - Acme United Corporation announced that its Canadian subsidiary has acquired the assets of First Aid Central, a Canadian first aid and safety supplier. The company had revenues in 2019 of approximately C$4.3M. The purchase price was not disclosed. The acquisition is expected to be accretive during 2020.

12:24 EST SeaWorld sees 2% increase in attendance for Q4 - The CEO of SeaWorld Serge Rivera said," Many of you have reached out asking for specifics around our results for 2019. As you know, since we are a publicly traded company we can't provide more details until we release earnings; however, I can provide some context around our attendance numbers. On a consolidated basis, we expect to report an increase in attendance of approximately 2% for the fourth quarter of 2019 when compared to the prior year quarter. During the quarter, many of our parks had some particularly strong attendance days, including some record days, which is exciting and we look forward to a productive 2020. Thank you to all our ambassadors for your help during the year and especially this past quarter. I will share more details and information after we release earnings." Shares of SeaWorld Entertainment are up 4.44% or $1.44 per share to $33.88 per share in afternoon trading.

12:05 EST Dover to acquire Systech International; terms not disclosed - Systech International announced that it has entered into a definitive agreement to be acquired by Dover Corporation. Following the close of the transaction, Systech will become part of Dover's Markem-Imaje business unit, a global supplier of product identification and traceability solutions, in Dover's Imaging and Identification segment. Terms of the transaction were not disclosed. The transaction is subject to satisfaction of customary closing conditions, including applicable regulatory approvals, and is expected to close in the first quarter of 2020. Atlas Technology Group and Chiesa Shahinian & Giantomasi, PC acted as financial advisor and legal advisor, respectively, to Systech.

12:04 EST Ametek to sell Reading Alloys business to Kymera International - Kymera International, a specialty materials company, announced that it has entered into a definitive agreement with AMETEK under which it will acquire AMETEK's Reading Alloys business, a provider of highly engineered materials for mission critical applications in the aerospace, defense, medical and industrial markets. Kymera has been owned by affiliates of Palladium Equity Partners, LLC, a middle market private equity firm with approximately $3B in assets under management, since 2018. The transaction, the terms of which were not disclosed, is expected to close in the first quarter of 2020. It is subject to customary closing conditions including applicable regulatory approvals.

12:01 EST Fiat Chrysler appoints Simon Sproule as Chief Communications Officer - Fiat Chrysler Automobiles announced Simon Sproule as its Chief Communications Officer. In addition, Sproule was named Head of North America Communications. The appointment is effective February 3, 2020. Sproule joins FCA from Aston Martin Lagonda where he served as Vice President and Chief Marketing Officer.

12:00 EST Valaris falls -8.9% - Valaris is down -8.9%, or -69c to $7.01.

12:00 EST Pacific Drilling falls -11.3% - Pacific Drilling is down -11.3%, or -72c to $5.61.

12:00 EST OneConnect rises 12.3% - OneConnect is up 12.3%, or $1.34 to $12.20.

11:55 EST Premier Oil jumps after signing deal to buy assets from BP , Dana - According to an earlier report from insider.co.uk, North Sea driller Premier Oil (PMOIY ) has signed deals worth up to GBP 662M to buy assets from BP and Dana, and plans to tap investors for around GBP 380M to fund the purchases.Shares of Premier Oil are up 15% or 20c per share to $1.48 per share in late morning trading. Reference Link

11:15 EST Chesapeake Utilities announces FERC approval of Del-Mar Energy Pathway Project - Chesapeake Utilities announced today that the Federal Energy Regulatory Commission has issued an order approving the Company's proposed Del-Mar Energy Pathway Project. The order, which was applied for in September of 2018 by Eastern Shore Natural Gas Company, Chesapeake Utilities' interstate natural gas transmission subsidiary, approves the construction and operation of new infrastructure facilities in Kent and Sussex counties in Delaware, and Wicomico and Somerset counties in Maryland. The project will add approximately 12 miles of natural gas infrastructure in Kent and Sussex counties and nearly seven miles of infrastructure in Wicomico and Somerset counties. Construction of the Del-Mar Energy Pathway Project is expected to commence within the first quarter of 2020. The estimated completion date will be the fourth quarter of 2021. Once in service, the new natural gas infrastructure will provide approximately 11.8M cubic feet per day of additional natural gas firm transportation service and 2.5M cubic feet of off-peak transportation service to Chesapeake Utilities' natural gas distribution subsidiaries on the Delmarva Peninsula and one industrial customer. The estimated cost of the project is approximately $37M. The anticipated annual gross margin for the Del-Mar Energy Pathway Project is $5.1M.

10:52 EST MySize to release MySizeID app version 2.0 at NRF 2020 show - My Size announced that it will be releasing the MySizeID app version 2.0, packed with new features at the National Retail Federation 2020 show on January 12-14. Ronen Luzon, CEO of My Size, commented, "We are very excited to launch the latest version of the MySizeID app at NRF 2020, the world's largest retail conference. Our latest features include new tutorials that enhance the personalized shopping experience for men and women, including the new FIT feature, which shows consumers how a garment will fit them in different sizes and allows them to personalize different preferences such as longer/shorter sleeve or pants length. We also added a new analytics dashboard for retailers, which will allow them to gain important sizing data on their customers."

10:11 EST Nike announces multi-year partnership with Liverpool FC - Nike will become Liverpool Football Club's official kit provider beginning in the 2020-21 season as part of a multi-year agreement, the company announced. As official kit supplier, commencing June 1, 2020, the agreement will see Nike outfitting the men's, women's and academy squads, as well as coaching staff and Liverpool Football Club Foundation. Reference Link

10:04 EST Casey's General Stores launches Casey's Rewards loyalty program - Casey's General Stores is announcing Casey's Rewards, its first-ever loyalty program, providing its guests across 16 states the ability to earn points on everyday purchases and redeem them for Casey's Cash, fuel discounts, or donate to a local school of their choice. The ability for Casey's Rewards members to turn points they have earned into a donation to local schools is called Cash for Classrooms. Casey's Rewards enables guests to easily earn and track points on eligible purchases, any way they shop at Casey's - in-store, online, at the pump, or over the phone. As soon as guests earn 250 points, they can redeem them in a variety of ways, including converting points into Casey's Cash, which can be used to pay for items inside the store, redeem points for cents off of fuel, or turn points into a donation to a local school of their choice. Guests will earn 10 points for every full $1 spent on eligible purchases in-store, online or over the phone. At the pump, guests will earn five points for every full gallon of fuel purchased. And, for every 10 large pizzas purchased, guests will get one free.

09:47 EST Sinopec Shanghai falls -3.2% - Sinopec Shanghai is down -3.2%, or -$1.01 to $30.45.

09:47 EST Eros International rises 5.2% - Eros International is up 5.2%, or 19c to $3.85.

09:47 EST Apache rises 19.0% - Apache is up 19.0%, or $4.86 to $30.50.

09:38 EST Comtech announces award of $211M Marine Corps contract - Comtech Telecommunications (CMTL) announced that during its second quarter of fiscal 2020, its Orlando, Florida-based subsidiary, Comtech Systems, which is part of Comtech's Government Solutions segment, was awarded a 10-year, $211M indefinite delivery/indefinite quantity contract by the Cubic Mission Solutions business division of Cubic Corporation (CUB) to provide next generation troposcatter systems in support of the U.S. Marine Corps. In connection with this contract award, Comtech received an initial $13.4M order to supply next generation terminals to Cubic. Delivery of the first units will support test and evaluation for the U.S. Marine Corps.

09:25 EST Dominion selects Siemens Gamesa Renewable Energy as turbine supplier - Dominion Energy of Siemens Gamesa Renewable Energy as project's preferred turbine supplier. A competitive solicitation process identified Siemens Gamesa as the optimal supplier. Once completed, the offshore wind project located 27 miles off the coast of Virginia Beach will produce enough zero-carbon electricity to power 650,000 Virginia homes at rated wind speed. As part of the preferred supplier agreement, Siemens Gamesa will supply turbines from its proven Offshore Direct Drive platform with the final turbine numbers to be determined during a later phase of the early development period. The agreement will support the submission of the project's Construction and Operations Plan to the Bureau of Ocean Energy Management in late 2020. In addition, Siemens Gamesa and Dominion Energy will work together to evaluate offshore wind supply chain development opportunities in Virginia as part of an effort to reduce project costs for the benefit of customers. The project will be located in 112,800 acres off the coast of Virginia Beach that Dominion Energy secured via lease from BOEM in 2013. The company began construction in June on a pilot offshore wind power project. The two six-megawatt turbines manufactured by Siemens Gamesa will be installed this spring and are on schedule to come online later this year.

09:23 EST Tyler Technologies signs 5-year SaaS agreement with city of Oxnard, CA - Tyler Technologies announced it has signed a five-year, software-as-a-service, or SaaS, agreement with the city of Oxnard, California, for an integrated ERP solution to replace the city's 30-year-old legacy system. The city selected enterprisewide modules from Tyler's Munis enterprise resource planning solution, EnerGov civic services suite, ExecuTime time and attendance applications, and Socrata Open Finance public data access and analysis portal.

09:16 EST Canon awarded group purchasing agreement with Premier - Canon U.S.A. has been awarded a group purchasing agreement with Premier, a leading healthcare improvement company, in the Managed Print Services, devices and accessories categories. Premier members now have access to Canon's full range of award-winning document scanners, multifunction printers, or MFPs, digital production printers, software and services.

09:12 EST Fly Intel: Pre-market Movers - HIGHER: Apellis Pharmaceuticals (APLS), up 45% after announcing that pegcetacoplan met the study's primary efficacy endpoint, demonstrating superiority to eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16... Tesla (TSLA), up 1% after Reuters reports the company has started work on building Model Y SUVs at its Shanghai plant. CEO Elon Musk said, "Ultimately Tesla Model Y will have more demand than probably all the other cars of Tesla combined."... Himax (HIMX), up 8% after reporting preliminary Q4 earnings... Microchip (MCHP), up 4% after announcing its revised Q3 revenue outlook. UP AFTER EARNINGS: AngioDynamics (ANGO), up 1%. LOWER: Alexion (ALXN), down 2% after Apellis reported top-line data showing that pegcetacoplan demonstrated superiority to its Soliris, or eculizumab... Kamada (KMDA), down 4% after announcing Q4 and FY19 revenue expectations below consensus. Also, the company's CEO Amir London said "...while the planned transition of GLASSIA manufacturing to Takeda is expected to decrease our revenue and profitability during the years 2021 and 2022, our continued business development efforts are expected to result in resumed revenue and profitability growth beginning in 2023." ... Crowdstrike (CRWD), down 1% after a 5M share block trade priced at $53.80... Alexandria Real Estate (ARE), down 3% after its 6M share secondary offering priced at $155.00.

09:10 EST Polar Power receives EPA certification for Toyota 1KS natural gas, LPG engines - Polar Power announced it has received certification from the Environmental Protection Agency for Toyota 1KS natural gas and LPG engines used in Polar's DC power systems. As part of Polar Power's ongoing diversification strategy, the company has been working to introduce lower emission, fuel efficient prime power and solar hybrid power systems targeting telecom, residential and commercial markets in sub 40 kw microgrid applications. Polar's engineering team has worked for over twelve months to integrate proprietary control technology with a long-life Toyota engine and Bosch engine controls designed to address the growing market for prime power, CHP and backup power needs worldwide. Polar is currently the only US company to achieve EPA certification for this Toyota 1KS engine that operates on natural gas and LPG.

09:08 EST Atlas Air announces ACMI placement with EL AL - Atlas Air Worldwide Holdings announced that its Atlas Air, Inc. unit and EL AL Israel Airline Ltd. have entered into an agreement that enables EL AL to expand its reach and cargo lift for its customers. Under the terms of the ACMI agreement, Atlas Air will operate a Boeing 747-400 Freighter for capacity on significant routes, mainly Liege - Tel Aviv, beginning in January 2020. The 747-400 will provide additional revenue cargo volume to serve the strong growth in demand across EL AL's freight network.

09:06 EST Digerati to continue to focus on driving long-term sales, revenue growth - Digerati Technologies announced its strategic initiatives and outlook for FY2020 ended July 31, 2020. Management continues to be focused on driving long-term sales and revenue growth, profitability, and enhancing shareholder value. The Company's plan to successfully meet its corporate goals and objectives includes: A continued focus on its core UCaaS/cloud communication business, which operates in a segment of the telecommunication industry that continues to experience significant growth as businesses migrate from legacy phone systems to cloud-based telephony systems. Continued enhancements to its broadband product portfolio that include an emphasis on marketing leading-edge network and business continuity solutions like SD-WAN, and its 4g LTE mobile data solution. The Company anticipates that these data centric solutions in demand by the business market will lead to an increase in average revenue per customer. Continued emphasis on its recurring revenue business model and building on its solid operational and financial foundation of $6.4M in annualized revenue to improve cash-flow profitability. Acceleration of its M&A activities targeting local and/or regional UCaaS/cloud telephony providers, which have excelled in their market with that "local" touch when serving their business customers. The Company will continue with its disciplined approach of future acquisitions and only acquire industry peers that meet key operational, technical, and financial criteria. A continued focus on the U.S. market of SMBs, which remains a high-growth market as businesses migrate from legacy phone systems to cloud-based communication solutions. A continued emphasis on Channel Management and the Company's Agent/Channel Partner sales strategy that includes enabling Value Added Resellers to offer cloud and session-based communication services to the enterprise market, primarily the SMB. Continued enhancement of its infrastructure and back office systems to streamline operations and automate processes for efficiency, all which support both its organic and acquisition growth model. Continued implementation of a total "pre" and "post" sales support model for building a world-class service delivery and help desk organization. During FY2019, Digerati integrated two acquisitions that created a solid foundation for continued growth and for achieving its corporate objectives. The Company's business, that operates as T3 Communications in Texas and Florida, serves over 700 business customers and 10,000 users across a broad range of industries including banking, healthcare, financial services, automotive, legal, real estate, staffing, and government. On September 24, 2019, the Company announced that it had entered into a definitive agreement to acquire Nexogy, a "white label" provider of cloud communication and broadband solutions tailored for businesses based in Miami, Florida and serving over 1,500 SMB accounts and 14,000 users. On a trailing twelve months pro forma basis, the combination of T3 and Nexogy will generate $12.7M in annual revenue, while the consolidation of telecom infrastructure and integration of cloud PBX platforms and back-office systems is expected to produce cost savings and EBITDA improvements.

09:05 EST Merck, genOway strengthen CRISPR/Cas9 strategic alliance - genOway announced an important milestone in extending its strategic alliance with Merck. In December 2018, genOway acquired from Merck exclusive worldwide rights on its foundational CRISPR/Cas9 portfolio in the rodent field. Now, the two companies have further strengthened their collaboration by entering into an additional license providing genOway with non-exclusive rights to commercialize the development and use of all other animal cell models for its customers' internal research uses as well as commercial exploitation.

09:03 EST Coupa Software acquires Yapta, terms not disclosed - Coupa Software announced that it has acquired travel price optimization leader Yapta. The acquisition enables Coupa to deliver more value across BSM by empowering companies to achieve greater savings in a significant spend category, Travel & Expense.

08:52 EST RADA Electronic announces new orders totaling over $6M in December - RADA Electronic announced that it has received a total of over $6M in new orders during the month of December 2019. The aggregate of new orders received in 2019 was $60M, an all-time record for the Company.

08:48 EST Inpixon's indoor mapping solution chosen by Chilean shopping mall - Inpixon announced it has been selected by Parque Arauco Kennedy Mall as their indoor mapping partner. Inpixon's indoor mapping platform, Jibestream, provides smart and fully customizable indoor mapping solutions and can be combined with the company's other indoor data solutions to deliver actionable indoor location data and intelligence.

08:44 EST Biomerica says Houston Methodist to begin enrollment for InFoods IBS trial - Biomerica announced that Houston Methodist will start enrollment for the clinical trial of its new InFoods(R) diagnostic-guided therapy to alleviate Irritable Bowel Syndrome symptoms. Houston Methodist will join Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, and the University of Michigan as primary enrollment centers for this study. The InFoodsendpoint trial is expected to be completed before 2020. Biomerica is now in the process of adding several new large medical groups to assist with accelerating the endpoint trial and participate in the subsequent pivotal trial needed for final FDA clearance. Further, by adding large world-renowned centers to its trials, Biomerica continues to grow the number of leading gastrointestinal physicians using the InFoods BS product during the trials and once FDA clearance is received. The patented Biomerica InFoods IBS product is designed to allow physicians to identify patient specific foods that when removed from the diet, may alleviate or improve an individual's IBS symptoms including constipation, diarrhea, bloating, abdominal cramps, pain and indigestion. The InFoods IBS point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample. A clinical lab version of the product is being used in this clinical trial. A billable CPT code that can be used by both clinical labs and physicians' offices is already available for InFoods IBS products. Market research conducted by a leading independent pharmaceutical marketing research firm determined that seventy percent of physicians surveyed would use the InFoods DGT without reimbursement and 90% would use it with reimbursement. The clinical trials are randomized, double-blinded, and placebo-controlled. Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, has completed its enrollment of patients for this endpoint study but will continue to participate in the final pivotal trial once that commences. The University of Michigan will continue to enroll patients in this endpoint trial along with Houston Methodist and others. This clinical endpoint trial is expected to be completed in approximately 9 months. If all goes as expected, Biomerica is looking to commence the final pivotal trial a few months thereafter, which is needed for submission to the FDA for final clearance. The endpoint trial stratifies enrollment by the three main IBS subclasses. There is currently no FDA cleared therapy for IBS-Mixed. The study design has already received a non-significant risk determination from FDA.

08:38 EST Trillium Therapeutics says Part 4 of TT1-621 study is 'ongoing' - A phase 1 multicenter, open-label study in which patients with advanced relapsed or refractory hematologic malignancies receive intravenous TTI-621 is currently in progress. The study consists of four parts: "Parts 1-3" in hematologic malignancies, with dosing up to 0.5 mg/kg, conducted under initial DLT criteria, now completed; and "Part 4" in cutaneous T-cell lymphoma, utilizing revised DLT criteria for thrombocytopenia and an amended protocol to allow for dosing above 0.5 mg/kg, now ongoing. Over 200 patients received doses ranging from 0.05 to 0.5 mg/kg, with the majority enrolled at 0.2-0.5 mg/kg dose levels. Updated safety data demonstrate that TTI-621 is generally well tolerated. The most frequent drug related adverse events were low-grade infusion reactions and transient thrombocytopenia that was not associated with bleeding. TTI-621 activity has been observed in patients across a range of hematologic malignancies. Notably, most patients were at an advanced stage of their disease and heavily pretreated, with median number of prior systemic treatments between 3 and 4. Part 4 of the study is now ongoing under an amended protocol. Given the transient nature of thrombocytopenia observed in Parts 1-3 of the study, the DLT definition for thrombocytopenia was revised, from Grade 4 of any duration in Parts 1-3, to Grade 4 lasting 72+ hours or a platelet count less than 10,000/microliter at any time in Part 4. As previously reported, 0.5 and 0.7 mg/kg dose levels have not shown any DLTs; furthermore no Grade 4 thrombocytopenia of any duration has been observed. The study is now dosing at the 1.0 mg/kg level, or five-fold the 0.2 mg/kg dose level where monotherapy effect was initially observed. The protocol stipulates 1.4 mg/kg as the next potential dosing level, and allows for higher dosing if appropriate. While the dose escalation is conducted with TTI-621 monotherapy, further clinical development strategy will pursue primarily combinations with other agents. The Company plans to provide a study update by mid-2020.

08:36 EST SiriusXM ended FY19 with 30M self-pay subscribers, exceeding guidance - SiriusXM announced it added 1.063 million net self-pay subscribers to finish 2019 with approximately 30M self-pay subscribers, exceeding the company's initial 2019 subscriber guidance. The company also announced that it expects to meet or exceed its 2019 guidance for revenue, adjusted EBITDA and free cash flow.

08:34 EST Iteris awarded $3.6M contract by OCTA for traffic signal synchronization - Iteris announced that it has executed the final contract and received the formal notice to proceed for a $3.6M initiative with the Orange County Transportation Authority, or OCTA, for a regional traffic signal synchronization project. The three-year project includes signal coordination and timing improvements, with the aim of improving traffic flow, enhancing public safety and decreasing stops. Under the project agreement, Iteris will provide services that will upgrade traffic signal electronics and communications equipment and optimize signal timing along Main Street, a north-south corridor that comprises major signalized intersections spanning three cities. As part of the project, Iteris' intersection-as-a-service end-to-end solution offering will deliver proactive monitoring of traffic signal operations at all project intersections. The primary goal of this project is to deploy new intelligent transportation system equipment and communication infrastructure to support the management of the cities' transportation network, implement optimized coordination timing plans to achieve optimal traffic flow, and improve safety for all road users, including vehicles, buses, bicycles and pedestrians.

08:29 EST SCWorx announces contract for utilization of ScanWorx service offering - SCWorx announced a further expansion of its customer base with a prestigious hospital system in the Northeast with a five-year, minimum $1M contract for its proprietary ScanWorx, the company's service offering. The agreement represents increased market validation of the company's ScanWorx application, which is its trademarked application and part of a suite of proprietary applications that collectively referred to as SCWorx, to significantly improve operating and financial performance by increasing automation involved in documenting cases in hospital procedural areas while simultaneously providing accurate information for use in patient billing systems.

08:27 EST Ovid Therapeutics expects long-term data from ENDYMION study in 1Q20 - Soticlestat is being evaluated in a comprehensive Phase 2 development program in DEE in collaboration with Takeda Pharmaceutical Company Limited. In September 2019, Ovid announced initial data from the ongoing Phase 2 open-label extension ENDYMION trial, demonstrating sustained and progressively-improving median seizure frequency reduction. Ovid plans to announce longer-term data from the ENDYMION open-label extension study in Q1 2020. Beyond the ENDYMION open-label extension study, Ovid and Takeda are also conducting the Phase 2 ARCADE and ELEKTRA trials in pediatric DEE patient populations. Initial data from the Phase 2 ARCADE study are expected in Q1 2020. ARCADE is a multicenter, open-label, pilot study that will evaluate the treatment of soticlestat in patients ages 2 to 35 years old with refractory epileptic seizures associated with CDKL5 Deficiency Disorder or Dup15q syndrome. The primary endpoint is the percent change in motor seizure frequency in patients treated with soticlestat by disorder. Topline results from the Phase 2 ELEKTRA study are expected in 2H 2020. ELEKTRA is an international, multicenter, randomized, double-blind, placebo-controlled study that will evaluate the treatment of soticlestat in approximately 126 pediatric patients ages 2 to 17 years old with seizures associated with Dravet syndrome or Lennox-Gastaut syndrome. The primary endpoint is the percent change from baseline in seizure frequency in patients treated with soticlestat compared to placebo. Despite the availability of medicines for epilepsy generally, there are few or no approved therapies for specific DEEs. Novel therapies are needed as current therapies fail to alter the course of the disease or address co-morbidities, and many patients suffer from resistant seizures despite treatment with multiple anti-epileptic drugs.

08:25 EST Ovid Therapeutics CEO says company enters 2020 in 'strong financial position' - Ovid Therapeutics outlined key clinical and business priorities for 2020. "Our focus in 2019 was on execution, building our senior leadership team and strengthening our balance sheet. As we look ahead to 2020, we enter the year in a strong financial position and will start to realize the potential impact that our hard work can deliver with multiple important clinical data readouts anticipated throughout the year," said Jeremy Levin, DPhil, MB, BChir, chairman and CEO of Ovid Therapeutics. "We expect new late-stage data from our two lead programs and across multiple indications in 2020. We will report the results of our pivotal Phase 3 NEPTUNE trial which, if successful, would make gaboxadol the first-ever treatment for Angelman syndrome. In addition, we will report data from the Phase 2 ROCKET signal-finding trial in Fragile X syndrome, a program that has the potential to provide a clinical path forward in this poorly served area. Finally, we are very excited to report updated data from soticlestat in rare epilepsies, which we believe could provide a clinically meaningful benefit to these patients who have limited options. 2020 is poised to be a pivotal year for our company and importantly, for the patients and families for which we strive every day to help."

08:20 EST Ondas Holdings says railroad completes deployment of pilot program - Ondas Holdings, through its wholly owned subsidiary, Ondas Networks, announced the completed deployment of the final phase of a three-phase pilot program for a leading North American Class 1 railroad. The railroad is using Ondas Networks' standards-based FullMAX software-defined radio platform for fixed and mobile data applications in multiple regions throughout the United States. The multi-phase, revenue-producing pilot program was designed to utilize 125 kHz of spectrum in the licensed 900 MHz frequency band, testing multiple data applications in connection with the project. The FullMAX SDR platform has demonstrated improved performance in terms of reliability, data throughput and latency - all relative to existing legacy network technologies - while operating over challenging terrain.

08:18 EST OncoCyte announces completion of CLIA Validation study of DetermaDX - OncoCyte Corporation announced the completion of the CLIA Validation study of DetermaDx, its liquid biopsy test in development to aid in ruling-out malignancy in lung nodules and potentially avoiding unnecessary invasive lung biopsies. With the completion of CLIA Validation, the Company will commence Clinical Validation, which, if successful, will establish the independent clinical performance of the test prior to commercial launch. Once Clinical Validation is completed and performance parameters are established, OncoCyte will begin preparations for commercial availability, including publication of the Clinical Validation results needed for CMS reimbursement dossier submission as well as the execution of additional clinical utility studies. DetermaDx is a multigene assay that measures gene expression in circulating blood cells and, in conjunction with certain clinical factors, may help rule out cancer in patients with lung nodules identified by CT scans. The completion of the CLIA Validation study confirms the reproducibility, accuracy and precision of the gene measurements and the combined multivariate assay. OncoCyte tested approximately 120 samples previously used in its R&D development study and successfully reproduced the results in the Company's CLIA laboratory.

08:15 EST Lake City Bank enters final phase of $21.7M investment - Lake City Bank announced that it has initiated the final phase of a $21.7M multi-year capital investment program in its Downtown Warsaw Campus and Kosciusko County offices. The $15.8M Downtown Warsaw Campus project, which began in 2010, has included significant capital investment in every one of the buildings the bank occupies. The bank's Warsaw Downtown Campus includes seven buildings and three surface level parking facilities. Today, nearly 350 Lake City Bank team members work in Downtown Warsaw. Lake City Bank also operates four full service offices within the city limits of Warsaw and 11 offices in Kosciusko County. Since 2010, each one of these offices has also been remodeled at a total investment of $5.9less than. These 11 offices employ 53 people.

08:12 EST Ventas appoints Carey Roberts as General Counsel - Ventas (VTR) announced today Carey Shea Roberts will join the company as Executive Vice President, General Counsel and Ethics and Compliance Officer, during the first quarter of 2020. In this role, Roberts will lead the company's legal, compliance and enterprise risk management functions, reporting to Debra Cafaro, Ventas Chairman and CEO. Roberts succeeds T. Richard Riney, the company's first General Counsel, who recently retired. Roberts joins Ventas from Assurant (AIZ), where she served as executive vice president, chief legal officer and corporate secretary.

08:09 EST Principia Biopharma announces expanded development program for rilzabrutinib - Principia Biopharma announced an expansion in the development of rilzabrutinib into IgG4-Related Disease (RD). This clinical program broadens the company's Bruton tyrosine kinase therapeutic areas and supports the company's commitment to innovate and solve high unmet needs. IgG4-RD is an immune-mediated disease of chronic inflammation and fibrosis that, if left untreated, can lead to severe morbidity including organ dysfunction and organ failure, which can be fatal. IgG4-related disease typically manifests with multiple organ involvement including but not limited to exocrine glands, GI tract organs, and kidneys. Principia believes rilzabrutinib can potentially lead to positive outcomes in IgG4-RD by impacting many of the driving features of the disease, including inflammation, allergic components, monocytes, macrophages, and B cells implicated in initiation and maintenance of disease. Treatment is typically glucocorticoids, however, patients often relapse after GCs are tapered and thus require chronic GC dosing, which can lead to severe and debilitating side effects. Rituximab has been shown to have an effective clinical response; however, patients frequently relapse after treatment as well. Recent advances in the field have led to recognition of this disease and the many unmet needs for the patients diagnosed with it. Awareness and recognition of IgG4-RD is growing and the exact prevalence remains unknown, with estimates ranging from 40,000 to 180,000 in the United States alone. The company anticipates initiating a Phase 2 clinical trial in the first half of 2020.

08:07 EST Perceptron appoints Bill Roeschlein as interim VP, finance and CFO - Perceptron announced that Bill Roeschlein has been named Interim Vice President, Finance and CFO, effective January 7, 2020. Roeschlein will report directly to Jay Freeland, Chairman of the Board and Interim President and CEO The Company plans to initiate a search for a permanent CFO under the guidance and direction of Perceptron's Board of Directors. Roeschlein served as CFO for Intermolecular.

08:07 EST AtriCure completes enrollment in aMAZE trial, receives FDA approval to continue - AtriCure announced the successful completion of patient enrollment in the aMAZE clinical trial. In addition, the company announced that it has received approval from the FDA for the continuation of the trial under a continued access protocol, or CAP, with an additional patient enrollment of up to 85 patients and the opportunity to further expand to 250 patients while the pre-market application is under review. The aMAZE trial is an FDA-approved, prospective, multicenter, randomized controlled, superiority-designed trial evaluating the Lariat Suture Delivery Device for LAA exclusion adjunctive to Pulmonary Vein Isolation, or PVI, catheter ablation for the treatment of persistent and long-standing persistent Afib. The objective of the aMAZE trial is to demonstrate that the Lariat device for LAA exclusion, plus PVI ablation, will safely and effectively lead to a reduced incidence of recurrent Afib compared to PVI alone. The aMAZE trial enrolled 600 total patients at 53 sites, and the primary effectiveness endpoint measure is freedom from episodes of Afib greater than 30 seconds at one-year post PVI. The company anticipates final patient follow-up in 2021 with final pre-market approval submission later in 2021.

08:06 EST Advaxis announces FDA clearance of IND for ADXS-504 for prostate cancer - Advaxis announced the U.S. Food and Drug Administration has cleared the Investigational New Drug application for the initiation of a Phase 1 clinical study of ADXS-504, the Company's ADXS-HOT candidate for prostate cancer. ADXS-HOT is the Company's off-the-shelf neoantigen clinical program targeting hotspot mutations that currently includes over ten cancer-type specific drug constructs in various stages of development.

08:04 EST Cellectar Biosciences appoints Igor Grachev as CMO - Cellectar Biosciences announced it has appointed Dr. Igor Grachev as CMO. Igor Grachev served as Global Development Leader and Head of Innovative Clinical Trials Initiative, R&D for TEVA Branded Specialty Pharmaceuticals, where he was responsible for the development, execution and management of clinical programs worldwide across all phases of clinical research, achieving regulatory approvals in multiple countries. Cellectar has granted to Dr. Grachev, effective as of his first day of employment with Cellectar, an option to purchase 80,000 shares of Cellectar's common stock at an exercise price per share equal to the closing price of Cellectar's common stock on the grant date as reported by Nasdaq. This grant was approved by the Compensation Committee of Cellectar's Board of Directors and made as an inducement material to Dr. Grachev entering into employment with Cellectar as contemplated by Nasdaq Listing Rule 5635(c)(4). The stock option, which has a 10-year term, vests and becomes exercisable in three equal annual installments beginning on the first anniversary from the date of Dr. Grachev's first day of employment. Cellectar provides this information in accordance with Nasdaq Listing Rule 5635(c)(4).

08:04 EST Pros Holdings appoints Nikki Brewer as Chief People Officer - Pros Holdings announced that Nikki Brewer has been appointed as Chief People Officer - a role responsible for furthering the PROS global people strategy and managing employment initiatives for the company's global employee base. In this role, Brewer reports directly to Andres Reiner, PROS President and CEO, and is responsible for overseeing the PROS global human resources function. A key focus for her team is creating and driving innovative employment initiatives that make PROS a destination technology company for outperformers, fueling the company's growth and enhancing the overall PROS employee experience. Brewer joined PROS in 2017 as Vice President of Total Rewards where she drove significant changes to the PROS benefit program, strengthened the PROS compensation process and program, and overhauled PROS human capital IT systems resulting in a vastly improved PROS employee experience.

08:03 EST eMagin receives approximately $1.4M displays order from Collins Aerospace - "This significant order for OLED microdisplays will support the delivery of F-35 Helmet Mounted Displays (HMD) supplied by Collins Elbit Vision Systems (CEVS) and extends our ongoing monthly display deliveries through third quarter 2020," stated CEO Andrew Sculley.

08:03 EST Accenture to acquire Symantec's Cyber Security Services business from Broadcom - Accenture (ACN) has agreed to acquire Symantec's Cyber Security Services business from Broadcom (AVGO). Financial terms were not disclosed. "Symantec's portfolio of Cyber Security Services includes global threat monitoring and analysis through a network of security operation centers, real-time adversary and industry-specific threat intelligence and incident response services. The six security operations centers are located in the U.S., the United Kingdom, India, Australia, Singapore and Japan. Its managed security services business is supported by a proprietary cloud-based platform that delivers a steady stream of technical and cyber adversary threat intelligence through a customizable portal." Completion of the acquisition is subject to customary closing conditions and is expected to close in March 2020.

08:01 EST Accenture to acquire Symantec's Cyber Security Services business from Broadcom

07:50 EST Tyme Technologies trading resumes

07:38 EST Ebix receives approval to begin insurance distribution in India - Ebix announced that its joint venture with Bombay Stock Exchange has received formal approval for Certificate of Registration to act as a direct insurance broker under the IRDAI Regulations, 2018. The venture, branded as BSE-Ebix Insurance Broking Pvt. Ltd., will enable distribution outlets, wealth management advisors, Point of Sale Persons to sell life and non-life insurance products. BSE-Ebix confirmed that it will soon announce a formal date for the go-live date of its distribution franchise. BSE-Ebix aims to offer numerous choices to customers, besides reaching to remote villages across India to access these products. The venture will make use of the reach of both BSE and EbixCash that spans over 3 lakh outlets across the country, and shall cover the entire insurance lifecycle from customer relationship management, agency management, multi-quoting, underwriting, policy creation, claims filing and settlement to back-end insurance policy administration.

07:35 EST Exelixis further expands prostate cancer cohort in Phase 1b COSMIC-021 trial - Exelixis announced that based on continued encouraging efficacy and safety data, the company plans to further expand the metastatic castration-resistant prostate cancer, or CRPC, cohort of COSMIC-021, the phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. The cohort, which was previously expanded from 30 to 80 patients in July 2019, will now include up to 130 patients. Based on preliminary encouraging activity, as determined by response assessment per Response Evaluation Criteria in Solid Tumors , and safety data of patients enrolled in the metastatic CRPC cohort, 50 additional patients with metastatic CRPC who have histologically or cytologically confirmed adenocarcinoma of the prostate are being enrolled in the trial.

07:32 EST Pacira says EXPAREL achieves primary, secondary endpoints in Phase 4 study - Pacira BioSciences announced that its Phase 4 study of EXPAREL in patients undergoing Cesarean section achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption while maintaining pain scores through 72 hours. EXPAREL demonstrated statistical significance for the key secondary endpoint of a reduction in the incidence and severity of itching for 72 hours after surgery. Full study results will be submitted for publication in the peer-reviewed medical literature later this year. The Phase 4, multicenter, randomized, active-controlled study across 18 clinical sites in the United States, enrolled 169 patients undergoing elective C-section. Patients were randomized to receive either 150 mcg morphine spinal anesthesia plus standard of care postoperative pain regimen, 50 mcg morphine spinal anesthesia plus EXPAREL transversus abdominis plane field block or opioid-free spinal anesthesia plus EXPAREL TAP block. Patients in the EXPAREL arms received a protocol-defined postoperative pain management regimen comprised of ketorolac, acetaminophen and ibuprofen. All patients could receive opioid rescue pain medicine upon request for breakthrough pain. The company's previous Phase 4 clinical study of EXPAREL in the C-section setting is awaiting publication in a peer-reviewed medical journal. That study demonstrated the superiority of an EXPAREL TAP block to a bupivacaine TAP block in patients undergoing C-section, achieving a 52% reduction in opioid use for EXPAREL-treated patients while also reducing pain scores through 72 hours post-surgery. Importantly, the study demonstrated a statistically significant higher percentage of opioid-spared patients in the EXPAREL group, with EXPAREL treated patients taking no more than one opioid tablet and experiencing no opioid-related side effects through 72 hours.

07:28 EST IGM Biosciences appoints Eric Humke as VP, clinical development, apoptosis - IGM Biosciences nnounced the appointment of Eric Humke, M.D., Ph.D., to the newly created position of VP, Clinical Development, Apoptosis. Humke will join Daniel Chen, CMO, and Wayne Godfrey, VP, Clinical Development, to lead the global clinical development of IGM's emerging pipeline of proprietary IgM antibodies. Humke joins IGM with more than 15 years of experience in apoptosis research and early clinical development of first-in-human therapeutics in solid tumors, most recently serving as Senior Medical Director at Genentech.

07:23 EST Apache, Total announce oil discovery offshore Suriname on Block 58 - Apache Corporation (APA) and Total S.A. (TOT) announced a significant oil discovery at the Maka Central-1 well drilled offshore Suriname on Block 58. The well was drilled using the drillship Noble Sam Croft with Apache as operator holding a 50% working interest and Total holding a 50% working interest. Maka Central-1 successfully tested for the presence of hydrocarbons in multiple stacked targets in the upper Cretaceous-aged Campanian and Santonian intervals and encountered both oil and gas condensate. The formation evaluation program included logging-while-drilling and wireline logs, formation pressures, and preliminary core and fluid analysis. Together with future appraisal wells, this data will be used to quantify the resource in the Campanian and Santonian formations. The shallower Campanian interval contains 50 meters of net hydrocarbon-bearing reservoir. Preliminary fluid samples and test results indicate light oil and gas condensate with API gravities between 40 and 60 degrees. The deeper Santonian interval contains 73 meters of net oil-bearing reservoir. Preliminary fluid samples and tests results indicate API oil gravities between 35 and 45 degrees. The Maka Central-1 also targeted a third interval, the Turonian, a geologic analogue to oil discoveries offshore West Africa. Prior to reaching this interval, the well encountered significantly over-pressured, oil-bearing reservoirs in the lower Santonian, and the decision was made to conclude drilling at approximately 6,300 meters. The pressures encountered in the lower Santonian are a positive sign for the Turonian and future drilling will test this interval.

07:22 EST Tyme Technologies, Eagle Pharmaceuticals announce strategic collaboration - Tyme Technologies (TYME) and Eagle Pharmaceuticals (EGRX) announced the formation of a U.S. strategic collaboration focused on the co-promotion of TYME's lead CMBT candidate oral SM-88 in advanced cancers. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells' protein synthesis, leading to a breakdown of the cancer's key defenses and cell death. In clinical trials, oral SM-88 has demonstrated complete or partial responses across 15 different cancers, including pancreatic, prostate, sarcoma, breast, lung, and blood cancers with minimal serious grade 3 or higher adverse events. Under the terms of the securities purchase agreement, TYME will receive a $20M upfront cash payment for 10M restricted shares of TYME common stock at $2.00 per share. In addition, TYME will receive a $20M milestone payment upon the successful completion of the first to occur of the following three events: achievement of the primary endpoint of overall survival in its TYME-88-Panc pivotal trial; or achievement of the primary endpoint of overall survival in the PanCAN Precision PromiseSM SM-88 registration arm; or FDA approval of SM-88 in any cancer. This payment would be split into a $10 million milestone cash payment and a $10M investment in TYME at a 15% premium to the then prevailing market price. Eagle's shares will be restricted from sale until the earlier of three months following the milestone event or the three-year anniversary of the agreement. Under the terms of the co-promotion agreement, Eagle Pharmaceuticals will undertake 25% of the promotional sales effort for SM-88 in the U.S. oncology market and receive 15% of the net U.S. revenues of SM-88, and TYME will be responsible for the remaining promotional effort. TYME will also be responsible for clinical development, regulatory approval, commercial strategy, marketing, reimbursement and manufacturing of SM-88. TYME retains the remaining 85% of net U.S. revenues and reserves the right to repurchase Eagle's co-promotion right for $200M. As part of this partnership between TYME and Eagle, there is also the potential to evaluate oral SM-88 in combination therapy or as monotherapy through leveraging Eagle's oncology pipeline and expertise in oncology settings, which may include trials in breast or lung cancers and other tumor types.

07:20 EST GeoPark announces Q4 operational update - GeoPark announced its operational update for Q4. Consolidated oil and gas production was up 8% to 41,786 boepd, or 10% adjusting for divested blocks. Production in Colombia increased by 9% to 33,311 boepd, or 12% increase adjusting for divested blocks. Production in Chile increased by 17% to 3,292 boepd. FY19 average production of 40,046 boepd, 11% higher than 2018 annual average levels, or 13% higher adjusting for divested blocks. Overall oil and gas production grew by 8% to 41,786 boepd in Q4 from 38,741 boepd in Q4 of 2018, due to increased production in Colombia and Chile, partially offset by lower production in Brazil. Oil represented 85% of total reported production compared to 84% in Q4. GeoPark's 2019 work program included 36 gross wells drilled, including development, appraisal and exploration wells. The company is drilling nine new exploration and development wells and testing three wells across its portfolio. The company expects the closing of the Amerisur acquisition this January. New independent reserves certification is expected to be released in early February.

07:18 EST Tyme Technologies trading halted, news pending

07:16 EST ADMA Biologics enters suppy agreement for plasma-derived intermediate fractions - ADMA Biologics announced its entry into a 5-year manufacturing and supply agreement with an undisclosed partner to produce and sell plasma-derived intermediate fractions from ADMA's U.S. Food and Drug Administration approved Immune Globulin manufacturing process. "A core element of our business strategy is to leverage and maximize the revenue we generate from the available manufacturing capacity at our FDA-approved plasma-derived products production facility. Through the production of our own marketed assets, BIVIGAM, ASCENIV and NABI-HB, we will now be able to generate additional revenue over and above the sales of the FDA-approved drugs themselves," said Adam Grossman, ADMA's President and CEO. "Based on current production and forecasted market sales volumes, we estimate that these additional revenues from the sale of these fractions will add between $5M and $10M to our annual revenues for 2020 and 2021 respectively. Depending on future plant capacity utilization and potential expansion, as well as our forecasted IG production ramp, we believe this contract has the potential to generate between $10M and $20M per year from 2022 through 2024. We are proud to be an emerging partner of choice for plasma-derived intermediate fractions and we look forward to providing high quality products to this new partner and delivering the highest level of service and value to all of our customers to support our overall growth objectives." With this newly executed agreement, ADMA is now able to further maximize the revenue per liter of plasma fractionated in the Boca Raton plant and sell these fractions so they may be processed by a third party into their own therapeutic products under their own licensed manufacturing processes.

07:13 EST Amicus says British MHRA issues PIM designation for AT-GAA - The British Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Promising Innovative Medicine designation for AT-GAA in late onset Pompe disease. A PIM designation signifies that a clinical program may be eligible for the Early Access to Medicines Scheme, which works to provide patients with life threatening or seriously debilitating conditions access to medicines with the potential to address an unmet medical need. PIM designation for AT-GAA is based on clinical efficacy results from the Phase 1/2 clinical study, including improvements in six-minute walk distance, an integrated measure of disease progression that evaluates the cardiopulmonary and musculoskeletal systems, as well as comparison to natural history of treated patients. Amicus is evaluating the EAMS program and will provide a future update.

07:11 EST Amicus completes patient enrollment in Phase 3 PROPEL study in Q4 - During the fourth quarter of 2019, Amicus completed and exceeded patient enrollment in the global Phase 3 PROPEL clinical study for Pompe disease. A total of 59 clinical sites have enrolled 123 patients globally. PROPEL is a 52-week, double-blind randomized study designed to assess the efficacy, safety and tolerability of AT-GAA compared to the current standard of care, alglucosidase alfa, an enzyme replacement therapy in adults with late-onset Pompe disease. The PROPEL study is intended to assess superiority of AT-GAA compared to alglucosidase alfa in both ERT switch and ERT naive patients. The primary efficacy endpoint is change in six-minute walk distance from baseline to Week 52. Secondary endpoints include respiratory measures and additional measures of muscle function and muscle strength.

07:09 EST Cellect Biotechnology provides update on patent applications - Cellect Biotechnology received official communication from two jurisdictions, the European Patent Office, or EPO, and the Israeli Intellectual Property Office, regarding their intention to grant European Patent Application No. 14851547.1 and Israeli Patent Application No. 244982, respectively. These patent applications include a cell-based product and a method of manufacturing a stem and progenitor cell population with enhanced activity by short incubation with an apoptotic ligand. The Company has previously published third-party data demonstrating improved "stemness" of stem cells. Specifically, it significantly improves both proliferation and functional capabilities of hematopoietic, or HSC, and mesenchymal, or MSC, stem cells originating from bone marrow, peripheral blood, umbilical cord and adipose tissue.

07:09 EST Apellis says Pegcetacoplan meets primary endpoint in Phase 3 study - Apellis Pharmaceuticals announced results from the Phase 3 PEGASUS study evaluating pegcetacoplan in adults with paroxysmal nocturnal hemoglobinuria. Top-line data show that pegcetacoplan met the study's primary efficacy endpoint, demonstrating superiority to eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16. At week 16, pegcetacoplan-treated patients had an adjusted mean hemoglobin increase of 2.4 g/dL from a baseline of 8.7 g/dL, compared to eculizumab-treated patients who had a change of -1.5 g/dL from a baseline of 8.7 g/dL. Additionally, pegcetacoplan showed promising results in key secondary endpoints. Pegcetacoplan met non-inferiority on transfusion avoidance and absolute reticulocyte count. Pegcetacoplan also showed positive trends on lactate dehydrogenase and fatigue as measured by the Functional Assessment of Chronic Illness Therapy-fatigue score. In this study, the safety profile of pegcetacoplan was comparable to eculizumab. Seven of 41 patients in the pegcetacoplan group experienced a serious adverse event, and 6 of 39 patients in the eculizumab group experienced SAEs. No cases of meningitis and no deaths were reported in either treatment group. The most common adverse events reported during the 16-week, randomized, controlled treatment period in the pegcetacoplan and eculizumab groups, respectively, were injection site reactions, diarrhea, headache and fatigue. Another common adverse event was hemolysis, which was reported in four patients in the pegcetacoplan group and nine patients in the eculizumab group. This led to the three discontinuations in pegcetacoplan group. All patients who completed the randomization period in both groups entered the 32-week open-label pegcetacoplan treatment period. Detailed results from the PEGASUS study will be presented at a future scientific meeting.

07:07 EST Bio-Techne rebrands Atlanta Biologicals portfolio of serum and media - Bio-Techne announced that the Atlanta Biologicals portfolio of serum and media will be rebranded as "R&D Systems." As part of the rebranding, the Atlanta Biologicals website will be retired and the entire serum and media portfolio, including product details and purchasing options, will be maintained through the R&D Systems website. Currently all serum and media products can be purchased through R&D Systems.

07:06 EST Bicycle Therapeutics, Cancer Research UK to collaborate on BT7401 development - Bicycle Therapeutics announced a second collaboration with Cancer Research UK in which Cancer Research UK will fund and sponsor development of BT7401, a multivalent Bicycle CD137 agonist, through a Phase IIa clinical study. Under the terms of the Clinical Development Partnerships agreement, Cancer Research UK's Centre for Drug Development will fund and sponsor development of BT7401 from current preclinical studies through the completion of a Phase IIa trial. Bicycle retains the right to advance the BT7401 program further, at which point an undisclosed payment split between cash and equity, success-based milestones and royalty payments would be made to Cancer Research UK.

07:05 EST Synthetic Biologics receives FDA guidance for SYN-004 Phase 1b/2a clinical trial - Synthetic Biologics announced the receipt of official meeting minutes from the U.S. FDA following a Type C meeting held on December 2, 2019 at the company's request to discuss the development of SYN-004 in allogeneic hematopoietic cell transplant recipients who are administered intravenous beta-lactam antibiotics in response to fever. "Our discussion with the FDA was extremely productive and reinforces our optimism in the potential of SYN-004 to prevent dysbiosis of the gut microbiome and significantly improve outcomes for patients who undergo allogeneic HCT and are treated with IV beta-lactam antibiotics," said Steven Shallcross, Chief Executive and Financial Officer of Synthetic Biologics. "We remain focused on working with the distinguished team at the Washington University School of Medicine in St. Louis to finalize the clinical program protocol in anticipation of the commencement of the Phase 1b/2a clinical study during the first quarter of 2020."

07:02 EST Genuine Parts announces sale of S.P. Richards' Canadian operations - Genuine Parts announced that it has completed the sale of its wholly-owned subsidiary, S.P. Richards Co. Canada, to Novexco, effective January 1. S.P. Richards Canada represents the company's Business Products Group in Canada. S.P. Richards Canada is a full-line, nationwide wholesaler of office supplies, furniture, technology products and facility and breakroom supplies, servicing office products re-sellers across the country from locations in Vancouver, Toronto, Calgary and Edmonton. In 2019, S.P. Richards Canada's approximate annual revenues were $50M. The company intends to use the cash proceeds from the transaction in line with its disciplined capital allocation strategy.

06:52 EST Kennametal provides update on FY20, FY21 restructuring actions - Kennametal provided an update on its progress toward previously announced restructuring actions. These actions are part of the company's ongoing simplification/modernization initiatives to enable a leaner structure and optimize its operations globally, including footprint rationalization and consolidation. The company recently completed the full closures of its manufacturing facilities in Lichtenau, Germany and Irwin, Pennsylvania, and consolidated those operations into other lower-cost and newly modernized Kennametal facilities. Additionally, it has completed negotiations with the employee representatives of the Neunkirchen, Germany, distribution center. Distribution activities have been transitioned to a third-party logistics provider. As expected, these actions will begin to reduce structural costs beginning in the second half of FY20. The closures and corresponding savings are part of the previously announced FY20 restructuring actions that are expected to result in annualized savings of $35M-$40M with pre-tax-charges of $55M-$65M. The company also expects to deliver the FY21 restructuring actions with the original estimated annualized savings of $25M-$30M, but with lower estimated pre-tax charges of approximately $55M-$65M, down from $60M-$75M. Following negotiations with local employee representatives, the company has agreed to downsize the Essen, Germany facility instead of the previously proposed closure. The facility will be substantially smaller with considerably lower operating costs. Additionally, a significant reduction in labor will take place as products are moved to other lower-cost Kennametal facilities. The agreement between Kennametal and the Essen employee representatives is effective through June 30, 2022. The company is also evaluating the acceleration of other facility closures as part of these restructuring activities.

06:47 EST Archer Daniels acquires Yerbalatina Phytoactives - ADM announced that it has acquired Yerbalatina Phytoactives, a pioneering natural plant-based extracts and ingredients manufacturer. "Yerbalatina's wide array of natural botanical extracts - including organic-certified ingredients - combined with their R&D capabilities and market expertise, are exciting additions to our pantry as we continue to build our leadership position in science-based microbiome solutions for human and animal health," said the company. Based in Brazil, Yerbalatina uses proprietary cool-drying technology to transform fruits, vegetables and other plants - such as acerola, acai, guarana and green coffee - into a wide variety of extracts and ingredients for customers in the food, beverage and health industries.

06:46 EST Avino Silver & Gold Mines appoints Nathan Harte as CFO - Avino Silver & Gold Mines announces the appointment of Nathan Harte as CFO. Nathan joined Avino in September 2016 as a Senior Accountant and was first promoted to the position of Assistant Corporate Controller, and subsequently promoted to Corporate Controller in June 2018.

06:32 EST Teleflex's UroLift System granted expanded indication by FDA - Teleflex announced that the FDA has granted the company an expanded indication for the use of its UroLift System to treat larger prostates, between 80cc and100cc. This minimally invasive, in-office treatment provides rapid relief and recovery from the symptoms of benign prostatic hyperplasia. BPH, also known as enlarged prostate, is non-cancerous enlargement of the prostate that occurs as men age. "This new indication marks another exciting milestone for Teleflex and an opportunity for hundreds of thousands more men to benefit from the UroLift System and the durable and lasting relief it can provide from burdensome BPH symptoms," said the company.

06:18 EST Diamondback Energy reports Q4 average daily production up 65% from last year - Diamondback Energy announced that its average daily production for the Q4 was 301.3 MBOE/d, or 195.0 MBO/d, an increase of 5% from Q3 average daily production of 287.1 MBOE/d and up 65% from Q4 2018 average daily production of 182.8 MBOE/d. Average daily production for the FY19 was 283.0 MBOE/d, an increase of 27% from combined 2018 average daily volumes of 222.1 MBOE/d, with oil volumes increasing 26% year over year, after adjusting for the full year 2018 impact of the Energen transaction which closed on November 29, 2018.

06:17 EST Precision Drilling sees 2019 year-end cash balance of approximately $75M - Precision anticipates a reported 2019 year-end cash balance of approximately $75M and in the fourth quarter completed a one-year extension of its $500M revolving credit facility, now maturing November 2023. Excluding letters of credit, the company's revolving credit facility remains undrawn, and with the year-end cash balance, Precision has access to over $700M in liquidity.

06:13 EST Burger King to test 'Impossible Croissan'wich' in select test markets - Burger King restaurants announces it is testing the new Impossible Croissan'wich sandwich. Starting late January in select test markets across the U.S. market, BK guests can now get the same breakfast Croissan'wich sandwich they know and love with a plant-based patty. The all-new, limited-time-only Impossible Croissan'wich features a toasted croissant, egg, cheese and a seasoned plant-based sausage from Impossible Foods. This test makes Burger King the first restaurant to test Impossible Sausage made from plants on a breakfast sandwich. Participating Burger King restaurants in Savannah, GA, Albuquerque, NM, Montgomery, AL, Lansing, MI and Springfield, IL will be testing the Impossible Croissan'wich. The Impossible Croissan'wich is made with 100% butter for a soft, flaky croissant piled high with a savory sizzling patty made from plants, fluffy eggs, and melted American cheese.

06:11 EST Precision Drilling raises 2020 CapEx view to $85M-$105M from $60M-$80M - Due to a change in Precision's estimate of rig componentization, certain costs that were previously classified as operating expenses will now be classified as maintenance capital. For 2020, this change is expected to decrease operating expenses and increase maintenance capital by an estimated $25M with no impact on cash flow. As a result, Precision's previously communicated 2020 capital expenditure plan of $60M-$80M is now expected to be $85M-$105M. Regarding the above announcements, Precision's CFO, Carey Ford stated: "Precision's proven ability to generate free cash flow has allowed the company to accelerate both its short and long-term debt reduction targets. Since 2018, we have reduced our debt by $412 million and used $26 million to repurchase our shares, totaling $438 million used to strengthen our balance sheet and return capital to shareholders. Precision remains well positioned to continue reducing debt, while maintaining financial flexibility to manage customer spending cycles, address the most attractive growth opportunities and opportunistically repurchase our shares. We are firm in our belief that these efforts are the most productive means to create shareholder value in the current market environment."

06:09 EST Incyte announces EMA validation of MAA for pemigatinib - Incyte announced the validation of the company's Marketing Authorization Application for pemigatinib for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy. The European Medicines Agency's validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process.

06:07 EST Blucora CFO Davinder Athwal to step down effective January 31 - Blucora announced that Davinder Athwal, CFO, will be stepping down from his role at the company, effective January 31, and will then be available in an advisory capacity through 2020. Rick Simonson has been retained as special advisor to the company as it conducts a thorough search for a permanent CFO.

06:03 EST Blucora to acquire HK Financial Services for $160M - Blucora announced it has entered into an agreement to acquire privately-held HK Financial Services, a CPA-focused, registered investment advisor. The combination adds approximately $4.4B to Blucora's total client assets, bringing the total to more than $72B, with approximately 42% in advisory assets. The acquisition is being structured as a stock purchase with a price of $160M, representing an attractive multiple of approximately 9.3x fully realized synergies on pro-forma 2020 EBITDA of HKFS. As part of the transaction Blucora expects to issue $165M of add-on term loan fungible with existing debt. The transaction is expected to close by the end of the first quarter of 2020, subject to regulatory approval and customary closing conditions.

05:37 EST Sapiens acquires sum.cumo for up to EUR 28.4M - Sapiens announced that it has acquired sum.cumo, the German-based technology provider that offers disruptive, digital, innovative and consumer-centric solutions mainly to the insurance sector, for up to EUR 28.4M. The acquisition will enable Sapiens to expand its footprint by offering Sapiens' complete product and services portfolio in the DACH region, alongside sum.cumo's offerings. Sapiens will continue to invest in and support sum.cumo's offerings, and enhance Sapiens' digital offerings worldwide via sum.cumo's solutions and expertise. The acquisition's primary goal is expanding Sapiens' presence in the DACH region. sum.cumo is expected to reach 2019 non-GAAP revenues of EUR 15M and low single-digit profitability. The total consideration is up to EUR 28.4M, including consideration for future retention and performance over the next four years. The acquisition will be accretive to profit starting from the second half of 2020. Consummation of the transaction is subject to certain regulatory approvals. The closing is expected for mid-Q1, 2020.

05:20 EST DXC Technology appoints Carla Christofferson as Chief Risk Officer - DXC Technology announced that Carla Christofferson has been appointed chief risk officer to lead the company's risk and security efforts. Christofferson will report to Mike Salvino, DXC's president and CEO, as a key advisor on embedded and emerging risks. Prior to joining DXC she was at AECOM where she served as executive vice president and chief legal officer.